OPR - Delayed Quote • USD ATXS Oct 2024 22.500 call (ATXS241018C00022500) Follow 0.1000 0.0000 (0.00%) At close: April 18 at 9:30 AM EDT Comparisons Indicators Technicals Corporate Events Chart Types Aggregated Types Draw Table View List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Date Close Open High Low Volume O H L C Vol AAPL Loading Chart for ATXS241018C00022500 1D 5D 1M 3M 6M YTD 1Y 2Y 5Y All Date Range 1 min 1 min 2 mins 3 mins 5 mins 15 mins 30 mins 1 hour 4 hours Recent News: ATXS Astria Therapeutics Appoints Sunil Agarwal to Its Board of Directors Chief Medical Officer Christopher Morabito Sells 10,000 Shares of Astria Therapeutics Inc (ATXS) Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Astria Therapeutics Announces Positive Initial Proof-of-Concept Results from the ALPHA-STAR Phase 1b/2 Trial of STAR-0215 for HAE Astria Therapeutics, Inc. (NASDAQ:ATXS) is favoured by institutional owners who hold 53% of the company Astria Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update Astria Therapeutics to Present at Upcoming American Academy of Allergy, Asthma & Immunology Annual Meeting Astria Therapeutics to Present at Upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference Chief Medical Officer Christopher Morabito Sells 10,000 Shares of Astria Therapeutics Inc Astria Therapeutics Announces Pricing of $125 Million Underwritten Offering Astria Therapeutics to Present STAR-0215 Data at the 2023 World Allergy Congress We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth
